[en] BACKGROUND: Approximately 85% of nasal polyps (NPs) in white subjects are characterized by prominent eosinophilia. IL-5 is the key driver of eosinophilic differentiation and survival. OBJECTIVE: We sought to investigate the therapeutic potential of inhibiting IL-5 with a humanized mAb as treatment for severe nasal polyposis. METHODS: Thirty patients with severe nasal polyposis (grade 3 or 4 or recurrent after surgery) refractory to corticosteroid therapy were randomized in a double-blind fashion to receive either 2 single intravenous injections (28 days apart) of 750 mg of mepolizumab (n = 20) or placebo (n = 10). Change from baseline in NP score was assessed monthly until 1 month after the last dose (week 8). Computed tomographic scans were also performed at week 8. RESULTS: Twelve of 20 patients receiving mepolizumab had a significantly improved NP score and computed tomographic scan score compared with 1 of 10 patients receiving placebo at week 8 versus baseline. CONCLUSION: Mepolizumab achieved a statistically significant reduction in NP size for at least 1 month after dosing in 12 of 20 patients. IL-5 inhibition is a potential novel therapeutic approach in patients with severe eosinophilic nasal polyposis.
Disciplines :
Otolaryngology
Author, co-author :
Gevaert, Philippe
Van Bruaene, Nicholas
Cattaert, Tom ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Van Zele, Thibaut
Acke, Frederic
De Ruyck, Natalie
Blomme, Katrien
Sousa, Ana R
Marshall, Richard P
Bachert, Claus
Language :
English
Title :
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.
Publication date :
2011
Journal title :
Journal of Allergy and Clinical Immunology
ISSN :
0091-6749
eISSN :
1097-6825
Publisher :
Mosby, St Louis, United States - Missouri
Volume :
128
Issue :
5
Pages :
989-995.e8
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright A(c) 2011 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
W. Fokkens, V. Lund, and J. Mullol European position paper on rhinosinusitis and nasal polyps 2007 Rhinol Suppl 20 2007 1 136
D. Polzehl, P. Moeller, H. Riechelmann, and S. Perner Distinct features of chronic rhinosinusitis with and without nasal polyps Allergy 61 2006 1275 1279 (Pubitemid 44465586)
T. Van Zele, S. Claeys, P. Gevaert, G. Van Maele, G. Holtappels, and P. Van Cauwenberge Differentiation of chronic sinus diseases by measurement of inflammatory mediators Allergy 61 2006 1280 1289 (Pubitemid 44465587)
D.L. Hamilos, D.Y. Leung, R. Wood, L. Cunningham, D.K. Bean, and Z. Yasruel Evidence for distinct cytokine expression in allergic versus nonallergic chronic sinusitis J Allergy Clin Immunol 96 1995 537 544
C. Bachert, P. Gevaert, G. Holtappels, S.G. Johansson, and P. Van Cauwenberge Total and specific IgE in nasal polyps is related to local eosinophilic inflammation J Allergy Clin Immunol 107 2001 607 614 (Pubitemid 32397745)
H. Riechelmann, T. Deutschle, A. Rozsasi, T. Keck, D. Polzehl, and H. Bürner Nasal biomarker profiles in acute and chronic rhinosinusitis Clin Exp Allergy 35 2005 1186 1191
A.E. Stoop, H.A. van der Heijden, J. Biewenga, and S. van der Baan Eosinophils in nasal polyps and nasal mucosa: an immunohistochemical study J Allergy Clin Immunol 91 1993 616 622 (Pubitemid 23062932)
C. Bachert, P. Gevaert, G. Holtappels, C. Cuvelier, and P. Van Cauwenberge Nasal polyposis: from cytokines to growth Am J Rhinol 14 2000 279 290
D.L. Hamilos, D.Y. Leung, D.P. Huston, A. Kamil, R. Wood, and Q. Hamid GM-CSF, IL-5 and RANTES immunoreactivity and mRNA expression in chronic hyperplastic sinusitis with nasal polyposis (NP) Clin Exp Allergy 28 1998 1145 1152 (Pubitemid 28432638)
H.U. Simon, S. Yousefi, C. Schranz, A. Schapowal, C. Bachert, and K. Blaser Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia J Immunol 158 1997 3902 3908 (Pubitemid 127488750)
P. Gevaert, C. Bachert, G. Holtappels, C.P. Novo, J. Van der Heyden, and L. Fransen Enhanced soluble interleukin-5 receptor alpha expression in nasal polyposis Allergy 58 2003 371 379 (Pubitemid 36605724)
C. Bachert, N. Zhang, J. Patou, T. Van Zele, and P. Gevaert Role of staphylococcal superantigens in upper airway disease Curr Opin Allergy Clin Immunol 8 2008 34 38
N. Zhang, G. Holtappels, C. Claeys, G. Huang, P. Van Cauwenberge, and C. Bachert Pattern of inflammation and impact of Staphylococcus aureus enterotoxins in nasal polyps from southern China Am J Rhinol 20 2006 445 450 (Pubitemid 44390224)
P.P. Cao, H.B. Li, B.F. Wang, S.B. Wang, X.J. You, and Y.H. Cui Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese J Allergy Clin Immunol 124 2009 478 484
N. Zhang, T. Van Zele, C. Perez-Novo, N. Van Bruaene, G. Holtappels, and N. De Ruyck Different types of T-effector cells orchestrate mucosal inflammation in chronic sinus disease J Allergy Clin Immunol 122 2008 961 968
S.J. Szabo, S.T. Kim, G.L. Costa, X. Zhang, C.G. Fathman, and L.H. Glimcher A novel transcription factor, T-bet, directs Th1 lineage commitment Cell 100 2000 655 669
P. Gevaert, D. Lang-Loidolt, A. Lackner, H. Stammberger, H. Staudinger, and T. Van Zele Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps J Allergy Clin Immunol 118 2006 1133 1141 (Pubitemid 44666979)
U. Tuncer, L. Soylu, B. Aydogan, F. Karakus, and C. Akcali The effectiveness of steroid treatment in nasal polyposis Auris Nasus Larynx 30 2003 263 268 (Pubitemid 36960231)
V.J. Lund, J. Flood, A.P. Sykes, and D.H. Richards Effect of fluticasone in severe polyposis Arch Otolaryngol Head Neck Surg 124 1998 513 518 (Pubitemid 28222339)
M. Pajek, A. Kubala-Kukuś, D. Banaś, J. Braziewicz, and U. Majewska Random left-censoring: a statistical approach accounting for detection limits in x-ray fluorescence analysis X-ray Spectrometry 33 2004 306 311
C. Beunckens, G. Molenberghs, and M.G. Kenward Direct likelihood analysis versus simple forms of imputation for missing data in randomized clinical trials Clin Trials 2 2005 379 386 (Pubitemid 41586022)
A.D. Klion, M.A. Law, P. Noel, Y.J. Kim, T.P. Haverty, and T.B. Nutman Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome Blood 103 2004 2939 2941 (Pubitemid 38451664)
J.K. Garrett, S.C. Jameson, B. Thomson, M.H. Collins, L.E. Wagoner, and D.K. Freese Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes J Allergy Clin Immunol 113 2004 115 119 (Pubitemid 38096170)
S.A. Joe, R. Thambi, and J. Huang A systematic review of the use of intranasal steroids in the treatment of chronic rhinosinusitis Otolaryngol Head Neck Surg 139 2008 340 347
P. Flood-Page, C. Swenson, I. Faiferman, J. Matthews, M. Williams, and L. Brannick A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma Am J Respir Crit Care Med 176 2007 1062 1071 (Pubitemid 350223751)
P. Haldar, C.E. Brightling, B. Hargadon, S. Gupta, W. Monteiro, and A. Sousa Mepolizumab and exacerbations of refractory eosinophilic asthma N Engl J Med 360 2009 973 984
M.E. Rothenberg, A.D. Klion, F.E. Roufosse, J.E. Kahn, P.F. Weller, and H.U. Simon Treatment of patients with the hypereosinophilic syndrome with mepolizumab N Engl J Med 358 2008 1215 1228 (Pubitemid 351439223)
S.G. Plötz, H.U. Simon, U. Darsow, D. Simon, E. Vassina, and S. Yousefi Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis N Engl J Med 349 2003 2334 2339 (Pubitemid 37521232)
Y.J. Kim, C. Prussin, B. Martin, M.A. Law, T.P. Haverty, and T.B. Nutman Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700 J Allergy Clin Immunol 114 2004 1449 1455 (Pubitemid 39575904)